US98422E1038
US98422E1038
Xeris Biopharma Holdings, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 291.845.000 | 203.070.000 | 43.7% |
| Cost of Revenue | 42.569.000 | 36.832.000 | 15.6% |
| Gross Profit | 249.276.000 | 166.238.000 | 50.0% |
| 224.380.000 | 199.884.000 | 12.3% | |
| Operating Income | 24.896.000 | -33.646.000 | 174.0% |
| Pretax Income | 554.000 | -57.104.000 | 101.0% |
| Net Income Common Stockholders | 554.000 | -54.836.000 | 101.0% |
| -- | -- | -- | |
| -- | -- | -- |